In conclusion, These findings suggest that HCETSR, derived from tRNA‐Glu/TTC, inhibits HCC malignancy via modulation of the SPTBN1/catenin axis and may represent a promising prognostic marker and therapeutic strategy for HCC. Here, SPTBN1 is linked to hepatocellular carcinoma.